MedTrace Logo

New Biomarker for Alzheimer's Disease Diagnostic

NCT01315639 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1067

Last updated 2025-09-12

No results posted yet for this study

Summary

The aim of this study is to examine the relationship between plasma putative biomarkers for Alzheimer's disease (i.e. Ab40 amyloid and total Ab42 amyloid, free, bound, free/bound, truncated, sAPPα) and :

* the risk of conversion of individuals with Mild Cognitive Impairment (MCI) into Alzheimer's disease (AD),
* the Alzheimer's disease progression rate.

Conditions

Interventions

BIOLOGICAL

biomarkers, MRI and CSF

MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0

Sponsors & Collaborators

  • URC-CIC Paris Descartes Necker Cochin

    collaborator OTHER

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Olivier Hanon, ph · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-03
Primary Completion
2015-02-26
Completion
2018-03-16

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01315639 on ClinicalTrials.gov